Calcitropic hormonal status in north Indian patients with end-stage renal disease

National Medical Journal of India

Volumn 12, Issue 5, 1999, Pages 202-207

  Singh, A K ^a   Avula, S ^a   Kher, V ^a   Rao, D S ^b   Mithal, A ^a,c  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^b Sleep Disorders and Research Center   (United States)

^c NONE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; OSTEOCALCIN; PARATHYROID HORMONE;

ADOLESCENT; ADULT; ARTICLE; BLOOD; BONE DISEASE; CHRONIC KIDNEY FAILURE; FEMALE; HUMAN; INDIA; MALE; MIDDLE AGED;

ADOLESCENT; ADULT; ALKALINE PHOSPHATASE; BONE DISEASES; FEMALE; HUMANS; INDIA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OSTEOCALCIN; PARATHYROID HORMONE;

EID: 0033182146     PISSN: 0970258X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Giorgio C, Mazzaferro S. Bone metabolism and its assessment in renal failure. Nephron 1994;67:383-401.
2. Antonsen JE, Sherrard DJ. Renal osteodystrophy: Past and present. Semin Dial 1996;9:296-302.
3. Hruska KA, Teitelbaum SL. Renal osteodystrophy. N Engl J Med 1995;333: 166-74.
4. Hory B, Drucke TB. The parathyroid-bone axis in uremia: New insights into old questions. Curr Opin Nephrol Hypertens 1997;6:40-8.
5. Sherrard DJ, Hercz G, Pei Y, Maloney NA, Greenwood C, Manuel A, et al. The spectrum of bone disease in end-stage renal failure - An evolving disorder. Kidney Int 1993;43:436-42.
6. Coburn JW, Salusky IB. Hyperparathyroidism in renal failure: Clinical features, diagnosis and management. Jn: Bilezikian JP, Levine MA, Marcus R (eds). The parathyroids. New York:Raven Press, 1994:721-45.
7. Pei Y, Hercz G. Low turnover bone disease in dialysis patients. Semin Dial 1996;9: 327-31.
8. Monier-Faugere MC, Malluche HH. Trends in renal osteodystrophy: A survey from 1983 to 1995 in a total of 2248 patients. Nephrol Dial Transplant 1996;11:111-20.
9. Fournier A, Oprisiu R, Said S, Sechet A, Ghazali A, Marie A, et al. Invasive versus non-invasive diagnosis of renal bone disease. Curr Opin Nephrol Hypertens 1997; 6:333-48.
10. 3 intake: Emergence of an idiopathic adynamic bone disease not related to aluminium. Nephron 1989;53:93-101.
11. Coburn JW, Frazao J. Calcitriol in the management of renal osteodystrophy. Semin Dial 1996;9:316-26.
12. Monier-Faugere M-C, Langub MC, Malluche HH. Bone biopsies: A modern approach. In: Avioli LV, Krane SM (eds). Metabolic bone disease and clinically related disorders. San Diego:Academic Press, 1998:237-73.
13. Wang M, Hercz D, Sherrard DJ, Maloney NA, Segre GV, Pei Y. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminium toxicity. Am J Kidney Dis 1995;26:836-44.
14. Hutchison AJ, Whitehouse RW, Boulton HF, Adams JE, Mawer EB, Freemont TJ, et al. Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. Kidney Int 1993;44:1071-7.
15. Urena P, Hruby M, Ferreira A, Ang KS. de Vernejoul MC. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol 1996;7:506-12.
16. Quarles LD, Lobaugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 1992;75:145-50.
17. Solal ME, Sebert JL, Boudalliez B. Marie A, Moriniere P, Gueris J, et al. Comparison of intact, midregion, and carboxyterminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialysed patients. J Clin Endocrinol Metab 1991;73:516-24.
18. Hercz G, Pei Y, Greenwood C, Manuel A, Saiphoo C, Goodman WG, et al. Aplastic osteodystrophy without aluminium: The role of 'suppressed' parathyroid function. Kidney Int 1993;44:860-6.
19. Sebert JL, Ruiz JC, Fournier A, Fardellone P, Gueris J, Marie A, et al. Plasma bone-Gla protein: Assessment of its clinical value as an index of bone formation in hemodialyzed patients. Bone Miner 1987;2:21-7.
20. Gundberg CM, Weinstein RS. Multiple immunoreactive forms of osteocalcin in uremic serum. J Clin Invest 1986;77:1762-7.
21. Malluche HH, Faugere MC, Fanti P, Price PA. Plasma levels of bone Gla-protein reflect bone formation in patients on chronic maintenance dialysis. Kidney Int 1984; 26:869-74.
22. Calvo MS, Eyre DR, Gundberg CM. Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev 1996;17:333-68.
23. Deftos LJ, Wolfert RL, Hill CS, Burton DW. Two-site assays of bone gla protein (osteocalcin) demonstrate immunochemical heterogeneity of the intact molecule. Clin Chem 1992;38:2318-21.
24. Lopez-Gavilanes E, Gonzales-Parra E, de la Piedra C, Caramelo C, Rapado A. Clinical usefulness of serum carboxyterminal propeptide of procollagen I and tartarate-resistant acid phosphatase determinations to evaluate bone turnover in patients with chronic renal failure. Mine r Electrolyte Metab 1994;20:259-64.
25. Mucsi I, Gavril H. Adynamic bone disease: Pathogenesis, diagnosis and clinical relevance. Curr Opin Nephrol Hypertens 1997;7:356-61.
26. Cohen-Solal ME, Shin M-S, Lundy MW, Parfitt AM. A new method for measuring cancellous bone erosion depth: Application to the cellular mechanisms of bone loss in postmenopausal osteoporosis. J Bone Miner Res 1991;6:1331-8.
27. Tian J, Smogorzewski M, Kedes L, Massry SG. PTH-PTHrP receptor mRNA is downregulated in chronic renal failure. Am J Nephrol 1994;14:41-6.
28. Fournier A, Yverneau PH, Hue P, Said S, Hamdini N, Eldin HM, et al. Adynamic bone disease in patients with uremia. Curr Opin Nephrol Hypertens 1994;3: 396-410.
29. Drucke TB. Abnormal skeletal response to parathyroid hormone and the expression of its receptor in chronic uremia. Pediatr Nephrol 1996;10:348-50.
30. Salusky IB, Ramirez JA, Oppenheim W, Gales B, Segre GV, Goodman WG. Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/ CCPD. Kidney Int 1994;45:253-8.
31. Pei Y, Hercz G, Greenwood C, Segre GV, Manuel A, Saiphoo C, Fenton S, et al. Risk factors for renal osteodystrophy: A multivariate analysis. J Bone Miner Res 1995;10:149-56.
32. Pei Y, Hercz G, Greenwood C, Segre GV, Manuel A, Saiphoo C, Fenton S, et al. Renal osteodystrophy in diabetic patients. Kidney Int 1993;44:159-64.
33. Goodman WG, Ramirez JA, Belin TR, Chon Y, Gales B, Segre GV, et al. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 1994;46:1160-6.
34. Cunnigham J, Makin H. How important is vitamin D deficiency in uraemia? Nephrol Dial Transplant 1997;12:16-18.
35. Mora-Palma FJ, Ellis HA, Cook DB, Dewar JH, Ward MK, Wilkinson R, et al. Osteomalacia in patients with chronic renal failure before dialysis or transplantation. Q J Med 1983;52:332-48.
36. Shen FH, Baylink DJ, Sherrard DJ, Shen L, Maloney NA, Wergedal JE. Serum immunoreactive parathyroid hormone and 25-hydroxyvitamin D in patients with uremic bone diseases. J Clin Endocrinol Metab 1975;40:1009-17.
37. Ritz E, Passlick-Deetjen J, Lippert J. What is the appropriate dialysate calcium concentration for the dialysis patient? Nephrol Dial Transplant 1996;11:91-5.
38. Bouillon R, Verberckmoes R, Moor PD. Influence of dialysate calcium concentration and vitamin D on serum parathyroid hormone during repetitive dialysis. Kidney Int 1975;7:422-32.
39. Monier-Faugere M-C, Malluche HH. Role of cytokines in renal osteodystrophy. Curr Opin Nephrol Hypertens 1997;6:327-32.
40. Parfitt AM. The hyperparathyroidism of chronic renal failure: A disorder of growth. Kidney Int 1997;52:3-9.
41. Tominaga V, Takagi H. Molecular genetics of hyperparathyroid disease. Curr Opin Nephrol Hypertens 1996;5:336-41.
42. Combe C, Aparicio M. Phosphorus and protein restriction and parathyroid function in chronic renal failure. Kidney Int 1994;46:1381-6.
43. Lafage MH, Combe C, Fournier A, Aparicio M. Ketodiet, physiological calcium intake and native vitamin D improve renal osteodystrophy. Kidney Int 1992;42: 1217-25.
44. Lucas PA, Brown RC, Woodhead JS, Coles GA. 1,25 dihydroxycholecalciferol and parathyroid hormone in advanced chronic renal failure: Effects of simultaneous protein and phosphorus restriction. Clin Nephrol 1986;25:7-10.
45. Aparicio M, Combe C, Lafage MH, de Precigout V, Potaux L, Bouchet JL. In advanced renal failure, dietary phosphorus restriction reverses hyperparathyroidism independent of changes in the levels of calcitriol. Nephron 1993;63:122-3.
46. Aterini S, Salvadori M, Ippollio E, et al. The role of vitamin D receptor gene alleles in the secondary hyperparathyroidism of hemodialysis patients. J Nephrol 1996; 9:201-6.
47. Rao M, Krishnaswamy H, Shastry JCM, et al. Renal osteodystrophy in patients with end-stage renal disease. Indian J Nephrol 1993;3:1-3.